NCT01692808

Brief Summary

The purpose of this study is to determine if high doses of vitamin D3 administered orally as adjunct therapy to children with Crohn's disease could improve the outcome of the disease.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
20

participants targeted

Target at below P25 for phase_2

Timeline
Completed

Started Oct 2012

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

September 17, 2012

Completed
8 days until next milestone

First Posted

Study publicly available on registry

September 25, 2012

Completed
6 days until next milestone

Study Start

First participant enrolled

October 1, 2012

Completed
2.1 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

November 1, 2014

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

November 1, 2014

Completed
Last Updated

November 3, 2015

Status Verified

November 1, 2015

Enrollment Period

2.1 years

First QC Date

September 17, 2012

Last Update Submit

November 2, 2015

Conditions

Keywords

Crohnvitamin Dremissioninflammationtolerance

Outcome Measures

Primary Outcomes (1)

  • Number of participants with adverse events after one month

    Tolerance will be assessed weekly by measuring clinical adverse events in relation with high blood level of 25 hydroxy vitamin D. Biological measures will also be performed including : Circulating level of Calcium, phosphorus, PTH.

    up to 1 month

Secondary Outcomes (3)

  • Decrease of inflammatory parameters

    Baseline and 1 month

  • Immunological changes

    Baseline and 1 month

  • Bioavailability

    Baseline, after 24 h and then weekly for one month

Study Arms (5)

Exclusive Enteral Nutrition

NO INTERVENTION

This group is one of the non interventional group. As enteral nutrition is one of the usual therapy of Crohn disease at diagnosis.

EEN + Vitamin D3 3000 UI daily

EXPERIMENTAL

Exclusive Enteral Nutrition + Vitamin D3 3000 UI daily for one month This arm will be one of the two experimental arms.

Drug: Vitamin D3 3000 UI daily

Corticosteroïd

NO INTERVENTION

Corticosteroids (1mg/kg/day) associated with usual vitamin and calcium supplementation: vitamin D 800 IU of vitamin D3 + 1000 mg calcium per day) for one month

Corticosteroids + Vitamin D3 4000 UI

EXPERIMENTAL

Corticosteroids (1mg/kg/day) associated with vitamin D3 4000 UI daily and calcium 1000 mg daily for one month

Drug: Vitamin D3 4000 UI daily

Vitamin D3 4000 UI

EXPERIMENTAL

Vitamin D3 4000 UI /day . This arm is intended for those children in remission with or without immunosuppressant. Vitamin D will be administered in adjunction to usual therapy.

Drug: Vitamin D3 4000 UI daily

Interventions

Vitamin D3 will be administered as an adjunct to corticosteroids or enteral nutrition at the doses of 3000 UI daily or 4000 UI daily

Also known as: Cholecalciferol
EEN + Vitamin D3 3000 UI daily

This arm is intended for those at diagnosis treated with Corticosteroid or in Remission

Also known as: Cholecalciferol
Corticosteroids + Vitamin D3 4000 UIVitamin D3 4000 UI

Eligibility Criteria

Age10 Years - 18 Years
Sexall
Healthy VolunteersNo
Age GroupsChild (0-17), Adult (18-64)

You may qualify if:

  • Age between 10 and 18 years
  • Crohn's disease diagnosed by usual clinical and endoscopic criteria
  • Recent (less than one week) blood test with results of : Albumin, sedimentation rate, hematocrit

You may not qualify if:

  • Known renal or cardiac malformation
  • Disorders of phospho-calcic metabolism and vitamin D
  • Intake of vitamin D supplementation in the last three months prior to enrollment
  • Current intake of medications known to interfere with the metabolism of calcium, phosphate and vitamin D \*

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Mother-child university hospital

Montreal, Quebec, H3T1C5, Canada

Location

Related Publications (2)

  • Jantchou P, Clavel-Chapelon F, Racine A, Kvaskoff M, Carbonnel F, Boutron-Ruault MC. High residential sun exposure is associated with a low risk of incident Crohn's disease in the prospective E3N cohort. Inflamm Bowel Dis. 2014 Jan;20(1):75-81. doi: 10.1097/01.MIB.0000436275.12131.4f.

    PMID: 24247650BACKGROUND
  • Nerich V, Jantchou P, Boutron-Ruault MC, Monnet E, Weill A, Vanbockstael V, Auleley GR, Balaire C, Dubost P, Rican S, Allemand H, Carbonnel F. Low exposure to sunlight is a risk factor for Crohn's disease. Aliment Pharmacol Ther. 2011 Apr;33(8):940-5. doi: 10.1111/j.1365-2036.2011.04601.x. Epub 2011 Feb 20.

MeSH Terms

Conditions

Crohn DiseaseInflammation

Interventions

Cholecalciferol

Condition Hierarchy (Ancestors)

Inflammatory Bowel DiseasesGastroenteritisGastrointestinal DiseasesDigestive System DiseasesIntestinal DiseasesPathologic ProcessesPathological Conditions, Signs and Symptoms

Intervention Hierarchy (Ancestors)

CholestenesCholestanesSteroidsFused-Ring CompoundsPolycyclic CompoundsSterolsVitamin DSecosteroidsMembrane LipidsLipids

Study Officials

  • Prevost Jantchou, MD, PHD

    mother-child university hospital Ste. Justine Montreal-Canada

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
phase 2
Allocation
RANDOMIZED
Masking
NONE
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Professor

Study Record Dates

First Submitted

September 17, 2012

First Posted

September 25, 2012

Study Start

October 1, 2012

Primary Completion

November 1, 2014

Study Completion

November 1, 2014

Last Updated

November 3, 2015

Record last verified: 2015-11

Locations